Al-Hendy A - Search Results

1

Uterine fibroids - Causes, impact, treatment, and lens to the African perspective.

Sefah N, Ndebele S, Prince L, Korasare E, Agbleke M, Nkansah A, Thompson H, Al-Hendy A, Agbleke AA. Sefah N, et al. Front Pharmacol. 2023 Jan 10;13:1045783. doi: 10.3389/fphar.2022.1045783. eCollection 2022. Front Pharmacol. 2023. PMID: 36703761 Free PMC article. Review.

2

Uterine Fibroids: A Podcast on Patient and Physician Perspectives on Medical Management and a New Medical Therapy (Relugolix Combination Therapy).

Venable SR, Al-Hendy A. Venable SR, et al. Adv Ther. 2023 Oct;40(10):4127-4133. doi: 10.1007/s12325-023-02595-x. Epub 2023 Aug 12. Adv Ther. 2023. PMID: 37568061 Free PMC article.

3

Gut and genital tract microbiomes: Dysbiosis and link to gynecological disorders.

Elkafas H, Walls M, Al-Hendy A, Ismail N. Elkafas H, et al. Front Cell Infect Microbiol. 2022 Dec 16;12:1059825. doi: 10.3389/fcimb.2022.1059825. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36590579 Free PMC article. Review.

4

Current and Emerging Treatment Options for Uterine Fibroids.

Ali M, Ciebiera M, Wlodarczyk M, Alkhrait S, Maajid E, Yang Q, Hsia SM, Al-Hendy A. Ali M, et al. Drugs. 2023 Dec;83(18):1649-1675. doi: 10.1007/s40265-023-01958-6. Epub 2023 Nov 3. Drugs. 2023. PMID: 37922098 Review.

5

GnRH analogs for the treatment of heavy menstrual bleeding associated with uterine fibroids.

Madueke-Laveaux OS, Ciebiera M, Al-Hendy A. Madueke-Laveaux OS, et al. F S Rep. 2022 Nov 21;4(2 Suppl):46-50. doi: 10.1016/j.xfre.2022.11.008. eCollection 2023 Jun. F S Rep. 2022. PMID: 37223760 Free PMC article.

6

Prevention of Uterine Fibroids: molecular mechanisms and potential clinical application.

Ali M, Bariani MV, Vafaei S, Omran MM, Yang Q, Madueke-Laveaux OS, Al-Hendy A. Ali M, et al. J Endometr Uterine Disord. 2023 Mar;1:100018. doi: 10.1016/j.jeud.2023.100018. Epub 2023 Feb 15. J Endometr Uterine Disord. 2023. PMID: 37637856 Free PMC article.

7

Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.

Stewart EA, Al-Hendy A, Lukes AS, Madueke-Laveaux OS, Zhu E, Proehl S, Schulmann T, Marsh EE. Stewart EA, et al. Am J Obstet Gynecol. 2024 Feb;230(2):237.e1-237.e11. doi: 10.1016/j.ajog.2023.10.030. Epub 2023 Oct 18. Am J Obstet Gynecol. 2024. PMID: 37863160 Free article. Clinical Trial.

8

Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.

Stewart EA, Lukes AS, Venturella R, Li Y, Hunsche E, Wagman RB, Al-Hendy A. Stewart EA, et al. Am J Obstet Gynecol. 2023 Mar;228(3):320.e1-320.e11. doi: 10.1016/j.ajog.2022.11.1278. Epub 2022 Nov 9. Am J Obstet Gynecol. 2023. PMID: 36370871 Free article. Clinical Trial.

9

A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies.

Al-Hendy A, Lukes AS, Poindexter AN 3rd, Venturella R, Villarroel C, Critchley HO, Li Y, McKain L, Arjona Ferreira JC, Langenberg AG, Wagman RB, Stewart EA. Al-Hendy A, et al. Pain Manag. 2023 Apr;13(4):205-211. doi: 10.2217/pmt-2022-0085. Epub 2023 May 15. Pain Manag. 2023. PMID: 37183454 Free article. Review.

10

Developmental reprogramming of myometrial stem cells by endocrine disruptor linking to risk of uterine fibroids.

Yang Q, Ali M, Treviño LS, Mas A, Al-Hendy A. Yang Q, et al. Cell Mol Life Sci. 2023 Aug 31;80(9):274. doi: 10.1007/s00018-023-04919-0. Cell Mol Life Sci. 2023. PMID: 37650943 Free PMC article. Updated.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

278 results

Search Page